prikaz prve stranice dokumenta Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination
  Download
PDF 886.81 KB
Scientific paper - Original scientific paper
Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination
Vaccines, 10 (2022), 11; 1813. https://doi.org/10.3390/vaccines10111813
Zember, Sanja; Bodulić, Kristian; Balent, Nataša Cetinić; Mikulić, Radojka; Markotić, Alemka; Đaković Rode, Oktavija

Cite this document

Zember, S., Bodulić, K., Balent, N. C., Mikulić, R., Markotić, A. & Đaković Rode, O. (2022). Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination. Vaccines, 10. (11). doi: 10.3390/vaccines10111813

Zember, Sanja, et al. "Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination." Vaccines, vol. 10, no. 11, 2022. https://doi.org/10.3390/vaccines10111813

Zember, Sanja, Kristian Bodulić, Nataša Cetinić Balent, Radojka Mikulić, Alemka Markotić and Oktavija Đaković Rode. "Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination." Vaccines 10, no. 11 (2022). https://doi.org/10.3390/vaccines10111813

Zember, S., et al. (2022) 'Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination', Vaccines, 10(11). doi: 10.3390/vaccines10111813

Zember S, Bodulić K, Balent NC, Mikulić R, Markotić A, Đaković Rode O. Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination. Vaccines [Internet]. 2022 October 28 [cited 2024 April 16];10(11). doi: 10.3390/vaccines10111813

S. Zember, K. Bodulić, N. C. Balent, R. Mikulić, A. Markotić and O. Đaković Rode, "Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination", Vaccines, vol. 10, no. 11, October 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:127:599037. [Accessed: 16 April 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Slower Waning of Anti-SARS-CoV-2 IgG Levels Six Months after the Booster Dose Compared to Primary Vaccination
AuthorSanja Zember
AuthorKristian Bodulić
AuthorNataša Cetinić Balent
AuthorRadojka Mikulić
AuthorAlemka Markotić
AuthorOktavija Đaković Rode
Author's institutionUniversity of Zagreb
School of Dental Medicine
(Chair of Infectology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Public Health and Health Care
Abstract (english)
Anti-SARS-CoV-2 IgG titer decreases rapidly after primovaccination, leading to a mandatory booster vaccination. We analysed anti-SARS-CoV-2 Spike RBD IgG levels (positive ≥ 50 AU/mL) in 405 healthcare workers (3010 sera) who received a booster dose (BD) 9 months after two-dose BNT162b2 primovaccination. Median antibody titer at the time of BD (582.6 AU/mL) was 1.7-fold and 16.4-fold lower than the peak titer after the first (961.5 AU/mL) and the second vaccine dose (SVD) (10,232.6 AU/mL), respectively. One month after vaccination, IgG titer increased 40.6-fold after BD compared with a 10.8-fold increase after primovaccination. Three months after vaccination, post-booster antibodies decreased significantly slower (2.2-fold) than after primovaccination (3.3-fold). At six months, antibodies decreased slower after BD (4.5-fold; median 5556.0 AU/mL) than after primovaccination (9.6-fold; median 1038.5 AU/mL). Antibody titers before and one month after BD correlated weakly (r = 0.30) compared with a strong correlation (r = 0.65) between the corresponding post-primovaccination titers. Pre-vaccination COVID-19 had no effect on IgG levels after BD compared with a positive effect after primovaccination. Despite high post-booster IgG levels, 22.5% of participants contracted mild COVID-19. The trend of IgG decline indicates the need for further revaccination, but the vaccine type should be defined according to viral mutations.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleVaccines
Numberingvol. 10, no. 11, 1813
e-ISSN2076-393X
DOIhttps://doi.org/10.3390/vaccines10111813
URN:NBNurn:nbn:hr:127:599037
Publication2022-10-28
Document URLhttps://www.mdpi.com/2076-393X/10/11/1813
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-11-29 10:48:43